{{Rsnum
|rsid=12201199
|Gene=TPMT
|Chromosome=6
|position=18139571
|Orientation=plus
|GMAF=0.1506
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=TPMT
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 90.8 | 9.2 | 0.0
| HCB | 97.8 | 2.2 | 0.0
| JPT | 95.6 | 4.4 | 0.0
| YRI | 24.2 | 51.6 | 24.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 97.8 | 2.2 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12201199
|Name_s=TPMT:rs12201199 A/T
|Gene_s=TPMT
|Feature=
|Evidence=PubMed ID:19898482
|Annotation=Risk or phenotype-associated allele: A. Phenotype: This variant was associated with cisplatin-induced hearing loss from a large candidate gene screen in 2 pediatric cohorts. Study size: 166 (54 discovery, 112 replication). Study population/ethnicity: Children with neoplasms receiving cisplatin; Canada. Significance metric(s): OR = 16.89 (CI 2.27-125.88); p = 0.00022 Type of association: CO; TOX; ADR
|Drugs=cisplatin
|Drug Classes=
|Diseases=Drug Toxicity; Ototoxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165291585
}}
{{omim
|id=613290
|rsnum=12201199
}}{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12201199
|overall_frequency_n=32
|overall_frequency_d=128
|overall_frequency=0.25
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=29
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}